

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales**  
(dollars in thousands--unaudited)

	<b>Three months ended</b>			
	<b>December 27, 2015</b>			
	<b>Net Sales As Reported</b>	<b>Legacy Tornier Stub Period (September 28, 2015 - September 30, 2015)<sup>1</sup></b>	<b>Legacy Tornier Net Sales Divested<sup>2</sup></b>	<b>Non-GAAP combined pro forma net sales</b>
<b>U.S.</b>				
Lower extremities	\$ 58,819	\$ 279	\$ —	\$ 59,098
Upper extremities	47,053	1,773	—	48,826
Biologics	15,971	66	—	16,037
Sports med & other	1,830	4	—	1,834
<b>Total extremities &amp; biologics</b>	<b>123,673</b>	<b>2,122</b>	<b>—</b>	<b>125,795</b>
Large joint	—	—	—	—
<b>Total U.S.</b>	<b>\$ 123,673</b>	<b>\$ 2,122</b>	<b>\$ —</b>	<b>\$ 125,795</b>
<b>International</b>				
Lower extremities	\$ 15,887	\$ 152	\$ —	\$ 16,039
Upper extremities	19,066	1,260	—	20,326
Biologics	4,582	13	—	4,595
Sports med & other	3,625	132	—	3,757
<b>Total extremities &amp; biologics</b>	<b>43,160</b>	<b>1,557</b>	<b>—</b>	<b>44,717</b>
Large joint	—	753	(753)	—
<b>Total International</b>	<b>\$ 43,160</b>	<b>\$ 2,310</b>	<b>\$ (753)</b>	<b>\$ 44,717</b>
<b>Global</b>				
Lower extremities	\$ 74,706	\$ 431	\$ —	\$ 75,137
Upper extremities	66,119	3,033	—	69,152
Biologics	20,553	79	—	20,632
Sports med & other	5,455	136	—	5,591
<b>Total extremities &amp; biologics</b>	<b>166,833</b>	<b>3,679</b>	<b>—</b>	<b>170,512</b>
Large joint	—	753	(753)	—
<b>Total net sales</b>	<b>\$ 166,833</b>	<b>\$ 4,432</b>	<b>\$ (753)</b>	<b>\$ 170,512</b>

<sup>1</sup> To add revenues from Legacy Tornier's fourth quarter for the period prior to the merger closing date when operations became consolidated.

<sup>2</sup> To reduce from Tornier's historical sales the global sales associated with Tornier's Large Joints business that have been reflected in discontinued operations.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Pro Forma Net Sales to Net Sales**  
(dollars in thousands--unaudited)

	Fiscal year ended				
	December 27, 2015				
	Net Sales As Reported	Legacy Tornier N.V. standalone nine months ended September 27, 2015 <sup>1</sup>	Legacy Tornier stub period (September 28, 2015 - September 30, 2015) <sup>2</sup>	Legacy Tornier Net Sales Divested <sup>3</sup>	Non-GAAP Combined Pro Forma Net Sales
<b>U.S.</b>					
Lower extremities	187,096	29,637	279	(9,733)	207,279
Upper extremities	58,756	115,846	1,773	—	176,375
Biologics	50,583	1,290	66	—	51,939
Sports med & other	3,388	5,021	4	—	8,413
<b>Total extremities &amp; biologics</b>	<b>299,823</b>	<b>151,794</b>	<b>2,122</b>	<b>(9,733)</b>	<b>444,006</b>
Large joint	—	119	—	(119)	—
<b>Total U.S.</b>	<b>\$ 299,823</b>	<b>\$ 151,913</b>	<b>\$ 2,122</b>	<b>\$ (9,852)</b>	<b>\$ 444,006</b>
<b>International</b>					
Lower extremities	51,200	7,402	152	—	58,754
Upper extremities	24,789	51,293	1,260	—	77,342
Biologics	19,652	357	13	—	20,022
Sports med & other	9,862	5,372	132	—	15,366
<b>Total extremities &amp; biologics</b>	<b>105,503</b>	<b>64,424</b>	<b>1,557</b>	<b>—</b>	<b>171,484</b>
Large joint	—	29,921	753	(30,674)	—
<b>Total International</b>	<b>\$ 105,503</b>	<b>\$ 94,345</b>	<b>\$ 2,310</b>	<b>\$ (30,674)</b>	<b>\$ 171,484</b>
<b>Global</b>					
Lower extremities	238,296	37,039	431	(9,733)	266,033
Upper extremities	83,545	167,139	3,033	—	253,717
Biologics	70,235	1,647	79	—	71,961
Sports med & other	13,250	10,393	136	—	23,779
<b>Total extremities &amp; biologics</b>	<b>405,326</b>	<b>216,218</b>	<b>3,679</b>	<b>(9,733)</b>	<b>615,490</b>
Large joint	—	30,040	753	(30,793)	—
<b>Total sales</b>	<b>\$ 405,326</b>	<b>\$ 246,258</b>	<b>\$ 4,432</b>	<b>\$ (40,526)</b>	<b>\$ 615,490</b>

<sup>1</sup> Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

<sup>2</sup> To add revenues from Legacy Tornier's fourth quarter for the period prior to the merger closing date when operations became consolidated.

<sup>3</sup> To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products that were divested prior to the merger and the global sales associated with Tornier's Large Joints business that have been reflected in discontinued operations.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Combined Pro Forma Average Sales per Day to Average Sales per Day**  
(dollars in thousands--unaudited)

	Three months ended		
	December 25, 2016		
	U.S.	International	Global
Net sales	\$ 143,065	\$ 49,958	\$ 193,023
Average sales per day (ASPD)	\$ 2,308	\$ 769	\$ 3,077
ASPD growth %	8.3 %	10.5 %	8.8 %
Impact of foreign currency exchange rates (FX) <sup>1</sup>	—	1,695	1,695
<b>Non-GAAP net sales, excluding the impact of FX</b>	<b>\$ 143,065</b>	<b>\$ 51,653</b>	<b>\$ 194,718</b>
Selling days	62	65	
<b>Non-GAAP ASPD, excluding the impact of FX</b>	<b>\$ 2,308</b>	<b>\$ 795</b>	<b>\$ 3,103</b>
<b>Non-GAAP pro forma ASPD constant currency growth % <sup>2</sup></b>	<b>11.4%</b>	<b>12.9%</b>	<b>11.8%</b>

  

	Three months ended		
	December 27, 2015		
	U.S.	International	Global
Legacy Wright	\$ 72,121	\$ 21,444	\$ 93,565
Legacy Tornier	51,552	21,716	73,268
Net sales, as reported	\$ 123,673	\$ 43,160	\$ 166,833
ASPD	\$ 2,132	\$ 696	\$ 2,828
Legacy Tornier stub period (September 28, 2015 - September 30, 2015) <sup>3</sup>	2,122	1,557	3,679
<b>Non-GAAP pro forma legacy Tornier</b>	<b>\$ 53,674</b>	<b>\$ 23,273</b>	<b>\$ 76,947</b>
Legacy Wright impact of revenue recognition <sup>4</sup>	(2,994)	—	(2,994)
<b>Non-GAAP adjusted legacy Wright</b>	<b>\$ 69,127</b>	<b>\$ 21,444</b>	<b>\$ 90,571</b>
Legacy Tornier selling days	61	65	
Legacy Wright selling days	58	62	
<b>Non-GAAP adjusted combined pro forma ASPD <sup>5</sup></b>	<b>\$ 2,072</b>	<b>\$ 704</b>	<b>\$ 2,776</b>

<sup>1</sup> The impact of FX on net sales is calculated by translating current year results at prior year average foreign currency exchange rates.

<sup>2</sup> Reflects growth of Q4 2016 Non-GAAP ASPD, excluding the impact of FX, over the Q4 2015 Non-GAAP adjusted combined pro forma ASPD.

<sup>3</sup> To add revenues from Legacy Tornier's fourth quarter for the period prior to merger closing date when operations became consolidated.

<sup>4</sup> Legacy Wright recognized approximately \$3 million during the fourth quarter of 2015, as result of conforming its methodology for revenue recognition with Legacy Tornier.

<sup>5</sup> Legacy Wright and Legacy Tornier have historically operated on different fiscal periods. In order to calculate pro forma sales growth, we have calculated average sales per day based on the respective legacy company and the associated geographic region, then added the legacy company ASPD together.

[Example: Q4 2015 Pro Forma Legacy Tornier U.S. Sales / Legacy Tornier U.S. Selling Days = \$880K. Q4 2015 Adjusted Legacy Wright U.S. Sales / Legacy Wright U.S. Selling Days = \$1,192K. Adjusted Pro Forma Combined Average Sales per Day = \$2,072K]

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended	Fiscal year ended
	December 25, 2016	December 25, 2016
<b>Gross profit from continuing operations, as reported</b>	\$ 142,440	\$ 497,955
<b>Gross margins from continuing operations, as reported</b>	73.8 %	72.1 %
Reconciling items impacting gross profit:		
Inventory step-up amortization	6,767	37,689
Transaction and transition costs	547	4,198
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 149,754</b>	<b>\$ 539,842</b>
Net sales from continuing operations	193,023	690,362
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>77.6%</b>	<b>78.2%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share**  
(dollars in thousands, except per share data--unaudited)

	Three months ended	Fiscal year ended
	December 25, 2016	December 25, 2016
<b>Net loss from continuing operations, as reported</b>	\$ (30,002)	\$ (164,934)
Net loss from continuing operations per share, as reported	(0.29)	(1.60)
Reconciling items:		
Inventory step-up amortization	6,767	37,689
Non-cash interest expense on convertible notes	10,755	36,567
Non-cash loss on extinguishment of debt	—	12,343
Derivatives mark-to-market adjustments	(1,813)	(28,273)
Transaction and transition costs	8,422	36,374
Management changes	—	1,348
CVR mark-to-market adjustments	(280)	8,688
Contingent consideration fair value adjustment	93	469
Legal settlement	—	1,800
Costs associated with new convertible debt	—	234
IRS settlement <sup>1</sup>	—	(3,073)
Tax effect of reconciling items <sup>2</sup>	(2,114)	(7,748)
Deferred tax benefit from acquired operations	(5,598)	(5,598)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	<b>\$ (13,770)</b>	<b>\$ (74,114)</b>
Add back amortization of intangible assets	7,434	28,841
<b>Adjusted non-GAAP earnings</b>	<b>\$ (6,336)</b>	<b>\$ (45,273)</b>
Weighted-average basic shares outstanding	103,309	102,968
<b>Adjusted non-GAAP earnings per share</b>	<b>\$ (0.06)</b>	<b>\$ (0.44)</b>

<sup>1</sup> IRS settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

<sup>2</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	<u>Three months ended</u>	<u>Fiscal year ended</u>
	<u>December 25, 2016</u>	<u>December 25, 2016</u>
<b>Net loss from continuing operations</b>	\$ (30,002)	\$ (164,934)
Interest expense, net	16,857	58,530
Benefit (provision) from income taxes	(6,493)	(13,406)
Depreciation	14,825	55,830
Amortization	7,434	28,841
<b>Non-GAAP EBITDA</b>	<b>\$ 2,621</b>	<b>\$ (35,139)</b>
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	4,515	14,416
Other expense (income), net	346	(3,148)
Inventory step-up amortization	6,767	37,689
Transaction and transition costs	8,422	36,374
Management changes	—	1,348
Legal settlement	—	1,800
Costs associated with new convertible debt	—	234
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 22,671</b>	<b>\$ 53,574</b>
Net sales from continuing operations	193,023	690,362
<b>Non-GAAP adjusted EBITDA margin</b>	<b>11.7%</b>	<b>7.8%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	<b>Three months ended</b>	<b>Fiscal year ended</b>
	<b>December 25, 2016</b>	<b>December 25, 2016</b>
<b>Net sales</b>	\$ 193,023	\$ 690,362
<b>Selling, general and administrative expense, as reported</b>	\$ 140,489	\$ 541,558
Selling, general and administrative expense as a percentages of net sales, as reported	72.8 %	78.4 %
<b>Reconciling items impacting selling, general and administrative expense:</b>		
Transaction and transition costs - selling, general and administrative	7,948	31,860
Management changes	—	1,348
Legal settlement	—	1,800
Costs associated with new convertible debt	—	234
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 132,541</b>	<b>\$ 506,316</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>68.7%</b>	<b>73.3%</b>
<b>Research &amp; development expense, as reported</b>	\$ 13,809	\$ 50,514
Research & development expense as a percentages of net sales, as reported	7.2 %	7.3 %
<b>Reconciling items impacting research &amp; development expense:</b>		
Transaction and transition costs - research & development	(73)	316
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 13,882</b>	<b>\$ 50,198</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>7.2%</b>	<b>7.3%</b>

\*\* In addition to the above reconciliations, the Company has provided reconciliations of non-GAAP combined pro forma financial information, including reconciliations of Q4 2016 non-GAAP combined pro forma sales growth for U.S. and International by product line, on Wright's website at [ir.wright.com](http://ir.wright.com) in the "Financial Information" section (see Wright-Tornier merger post Disc Ops – IR Presentation 2-21-2017). \*\*